RxDoctor Payments Data

Michelle Rivera-Resto, MD

Gastroenterology · Humacao, PRNPI 1982812376

Payments from drug & device makers

$1,702in general payments, 2019–2025

Across 71 payments — averaging $23.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$562
  • AbbVie$557
  • Johnson & Johnson$222
  • Eli Lilly Export S.A. Puerto Rico Branch$164
  • PBG Puerto Rico LLC$92
  • Madrigal Pharmaceuticals$25
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$1,702100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,702 in reported general payments places this provider in the 45th percentile of 198 gastroenterology providers in Puerto Rico.

See all gastroenterology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,348
Medicare patients
13
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$94,979
LinzessLinaclotide147$80,394
CreonLipase/Protease/Amylase32$36,308
Dexlansoprazole DrDexlansoprazole114$25,971
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates261$21,631
Sucralfate56$21,257
ClenpiqSod Picosulf/Mag Ox/Citric Ac117$21,228
Cholestyramine LightCholestyramine152$16,519
Mesalamine46$15,511
Famotidine1,194$8,292
SuprepSodium, Potassium,mag Sulfates69$8,066
Ursodiol87$7,968
DexilantDexlansoprazole18$5,628
Lansoprazole276$4,333
Omeprazole595$4,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$557$116,702179 claims
Ferring Pharmaceuticals Inc.Clenpiq$18$21,228117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 198 gastroenterology providers in Puerto Rico.

Other gastroenterology in Humacao

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →